<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617941</url>
  </required_header>
  <id_info>
    <org_study_id>CBGG492A2214</org_study_id>
    <secondary_id>2011-005316-28</secondary_id>
    <nct_id>NCT01617941</nct_id>
  </id_info>
  <brief_title>A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled, Study in Patients With Non-chronic Migraine to Assess the Efficacy, Safety and Tolerability of BID Oral Doses of BGG492 in Migraine Prevention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients
      with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of migraine attacks</measure>
    <time_frame>12 weeks</time_frame>
    <description>50% responder rate (equal to or more than 50 % reduction in attack frequency during the last 4-weeks of the 12-weeks treatment period compared with the 4-weeks Baseline period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of migraine attacks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in number of migraine attacks comparing the last 4-weeks treatment with the Baseline period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening</condition>
  <arm_group>
    <arm_group_label>BGG492</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGG492</intervention_name>
    <arm_group_label>BGG492</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female smoking and non-smoking subjects of 18 to 65 years of age (inclusive)

          -  Patients diagnosed with non-chronic migraine with or without aura of duration of at
             least 12 months prior to the study start

          -  Patient diagnosed with migraine (according to the International Headache Society
             categories 1.1 and with equal to/more than 3 and equal to/ less than 12 migraine
             attacks per 4 weeks for each of the last 6 months preceding the Screening

          -  Patients willing to abstain from activities that require focused attention, e.g.
             driving a car or other vehicles, operating machines or engaging in potentially
             dangerous activities that require focused attention and intact physical balance

        Exclusion Criteria:

          -  Patients diagnosed with basilar, ophthalmoplegic or hemiplegic migraine as shown in
             the current/past medical history.

          -  Patients having an experience of non-migraine headaches on more than 6 days per 4
             weeks in the past 6 months prior to study start

          -  Patients receiving regular treatment during the four (4) weeks preceding the Baseline
             with psychoactive drugs (e.g. hypnotics, benzodiazepines, neuroleptics) except
             antidepressants (eg. SSRIs, SNRIs, Tri- or Tetracyclics).

          -  Patients receiving migraine prevention medications during past three (3) months
             preceding Baseline

          -  Patients receiving topiramate as migraine prevention medication during past six (6)
             months preceding Baseline

          -  Patients receiving metamizole as acute treatment of migraine during past three (3)
             months preceding Baseline

          -  Patients using (or having used within four (4) weeks before the treatment start) drug
             treatments that are potent inhibitors of OATP transporters (e.g. rifampin).

          -  Any psychiatric condition (e.g., schizophrenia, dementia, bipolar disorder) as shown
             in the past medical history prior to study start

          -  Patients with recent (within the last three [3] years prior to study start) and/or
             recurrent history of autonomic dysfunction (e.g. recurrent episodes of fainting,
             palpitations, orthostatic hypotension etc.).

          -  Pregnant or nursing (lactating) women. Baselines (1 and 2).

          -  Patients with history of drug or alcohol abuse within the 12 months prior to dosing
             Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-chronic migraine, migraine prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

